Intra-Immusg private limited

27/02/2022

Dear All,
Sorry for our previous facebook link is not functional well.
Now, we are pleased to introduce our official website IISG:
https://www.intra-immusg.com/

If you are interested in the PRL3-zumab novel cancer immunotherapy. Please contact IISG CEO Charles Tang or IISG Founder at [email protected]

Thank you!

IISG is a phase 2 clinical-stage biotechnology company in Singapore and developer of cancer immunotherapies and traditional drugs with least side effects. Our first antibody drug, PRL3-zumab is on 2nd phase and expected to contribute to better life of cancer patients. Visit our website today!

23/07/2021

Intra-ImmuSG (IISG) website is alive:

https://www.intra-immusg.com/

05/08/2020

Ready to get started for phase II multi-center clinical trial in the USA for solid tumors: https://clinicaltrials.gov/ct2/show/NCT04452955?cond=PRL-3&draw=2&rank=1

14/06/2020

PRL3_zumab in phase II clinical trials for solid tumors: https://clinicaltrials.gov/ct2/show/NCT04118114

30/04/2020

A nice write-up at A*STAR Research

30/04/2020

A nice development

Just because a molecular target resides inside a cancer cell does not mean that it cannot be targeted by antibodies, says Qi Zeng, founder of A*STAR spin-off company Intra-ImmuSG.

03/09/2019

Channel News Asia news at https://www.channelnewsasia.com/news/singapore/singapore-scientists-new-cancer-drug-chemotherapy-alternative-11772274

03/09/2019

A*STAR Research Highlights at https://research.a-star.edu.sg/articles/highlights/targeting-cancer-from-the-inside-out/ #

03/09/2019

The discovery that intracellular oncoproteins can be externalized onto the surface of cancer cells for antibody therapy has opened up novel way of immunotherapy.

27/08/2018

Congratulations on Intra-ImmuSG for an exciting and historically important day today!